In this video, health care analyst David Williamson takes a look back on the week so far for the Food and Drug Administration advisory committee. A trifecta of recommendations for approval greeted investors, although not all thumbs-ups are equal. Watch and find out what this means for investors of the three companies.
This week was a trifecta of success for these biotechs.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid